08:41 AM EDT, 06/03/2024 (MT Newswires) -- Liquidia ( LQDA ) said Monday that the US District Court for the District of Delaware rejected a motion by United Therapeutics ( UTHR ) to block the launch of its inhalation powder, Yutrepia to treat pulmonary hypertension linked to interstitial lung disease.

The company said the ruling reinforces the clear path for the Food and Drug Administration to issue a final decision on the drug's amended new drug application.

Liquidia ( LQDA ) shares rose by nearly 12% in premarket trading.

Price: 14.25, Change: +1.38, Percent Change: +10.72